ClinicalTrials.gg
Status unknownNCT04884009Updated May 12, 2021

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

A Phase 2 interventional study of SHR-1701; Famitinib and SHR-1701 in Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination with or without famitinib malate for the treatment of extensive stage small cell lung cancer after the failure of previous systemic chemotherapy

02

Conditions studied

  • Lung Cancer

Browse trials for

03

In context

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

This study's planned enrollment of 106 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily participated in the clinical study, understood the study procedures and are able to sign the form.
  2. 18 to 75 years old, male or female.
  3. or cytologically confirmed extensive stage small cell lung cancer(ED-SCLC).
  4. Performance Status of 0 or 1.
  5. Adequate hematological, hepatic and renal function.
  6. Female subjects of must have a negative serum HCG test before treatment.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed mixed SCLC and NSCLC.
  2. Untreated central nervous system .
  3. Cancerous meningitis (meningeal metastasis).
  4. Uncontrolled pleural effusion, pericardial effusion or ascites.
  5. Tumor infiltration into the great vessels on imaging;
  6. Hemoptysis symptoms and maximum daily hemoptysis ≥ 2.5ml occurred within 1 month.
  7. Uncontrolled tumor-related pain.
  8. other than SCLC within 5 years.
  9. Systemic antitumor therapy was received 4 weeks prior to trial treatment.
  10. History of diseases.
  11. Significant cardiovascular disease.
  12. Inadequately controlled hypertension.
  13. Known history of testing positive test for or known AIDS.
  14. Patients with active or
  15. Severe infections within 4 weeks prior to trial treatment.
  16. Active tuberculosis.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    SHR-1701+ Famitinib

    Drug: SHR-1701; Famitinib

  • Experimental
    SHR-1701

    Drug: SHR-1701

Interventions

  • DrugSHR-1701; Famitinib

    SHR-1701+ Famitinib

  • SHR-1701

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) based on RECIST 1.1 criteria

    Time frame: up to approximately 1 year.

Secondary outcomes

  1. Progression free survival (PFS) based on RECIST 1.1 criteria

    Time frame: up to approximately 1 year.

  2. Disease control rate (DCR) based on RECIST 1.1 criteria

    Time frame: up to approximately 1 year.

  3. Duration of response (DoR)

    Time frame: up to approximately 1 year

  4. Overall survival (OS)

    Time frame: up to approximately 1 year

  5. AEs+ SAEs determined by NCI-CTCAE V5.0

    Time frame: Baseline until up to 90 days after end of treatment.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2021; primary completion for Dec 2022, 19 months later.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 19 months is below that.

Counting every sponsor, half of 363 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartEst.
May 31, 2021
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04884009
Responsible party
Sponsor
First posted
May 12, 2021
Start date
May 31, 2021 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
May 12, 2021

Study contacts

Wei Shi
Contact
wei.shi@hengrui.com
021-68868570
Huan Li
Contact
huan.li@hengrui.com
17721286513

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion